PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
January 14, 2026Journal of Clinical Oncology

Physical activity and molecular residual disease (MRD) in stage III colon cancer: Findings from CALGB (Alliance)/SWOG 80702.

View Full Paper
Ask AI
Bookmark
Share

Authors

GZGeorge Q. ZhangCMChao MaQSQian Shi

Discussion

Loading...

Member takes

Overview

Postoperative analysis reveals physical activity improves disease-free survival in colon cancer patients, suggesting benefits of celecoxib treatment.

Key Points

  • To evaluate the impact of physical activity on outcomes related to circulating tumor DNA in stage III colon cancer.
  • Post hoc analysis of a phase III trial comparing celecoxib vs. placebo and 3 vs. 6 months of adjuvant chemotherapy.
  • Self-reported physical activity assessed using metabolic equivalent hours per week at two timepoints.
  • MRD determined through a tumor-informed ctDNA assay.
  • Survival outcomes estimated using flexible parametric survival models.
  • Among 763 patients, disease-free survival improved in ctDNA negative patients with moderate to high physical activity levels.
  • DFS HR for moderately active ctDNA negative: 0.62, and highly active: 0.53.
  • No DFS benefit seen in ctDNA positive patients regardless of activity level.
  • Overall survival was not impacted by physical activity or ctDNA status.

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/6966f32713bf7a6f02c00f74https://doi.org/10.1200/jco.2026.44.2_suppl.163
View Full Paper
Ask AI
Bookmark
Share